| Literature DB >> 32824892 |
Silvia Reverté-Villarroya1,2, Antoni Dávalos3, Sílvia Font-Mayolas4, Marta Berenguer-Poblet1,2, Esther Sauras-Colón2, Carlos López-Pablo1,2, Estela Sanjuan-Menéndez5, Lucía Muñoz-Narbona3, Rosa Suñer-Soler6.
Abstract
New reperfusion therapies have improved the clinical recovery rates of acute ischemic stroke patients (AISP), but it is not known whether other factors, such as the ability to cope, might also have an effect. The aim of this study was to evaluate the effect of endovascular treatment (EVT) on coping strategies, quality of life, and neurological and functional outcomes in AISP at 3 months and 1 year post-stroke. A multicenter, prospective, longitudinal, and comparative study of a sub-study of the participants in the Endovascular Revascularization with Solitaire Device versus Best Medical Therapy in Anterior Circulation Stroke within 8 Hours (REVASCAT) clinical trial was conducted after recruiting from two stroke centers in Catalonia, Spain. The cohort consisted of 82 ischemic stroke patients (n = 42 undergoing EVT and n = 40 undergoing standard best medical treatment (BMT) as a control group), enrolled between 2013-2015. We assessed the coping strategies using the Brief Coping Questionnaire (Brief-COPE-28), the health-related quality of life (HRQoL) with the EQ-5D questionnaire, and the neurological and functional status using the National Institute of Health Stroke Scale (NIHSS), Barthel Index (BI), modified Rankin Scale (mRS), and Stroke Impact Scale-16 (SIS-16). Bivariate analyses and multivariate linear regression models were used. EVT patients were the ones that showed better neurological and functional outcomes, and more patients presented reporting no pain/discomfort at 3 months; paradoxically, problem-focused coping strategies were found to be significantly higher in patients treated with BMT at 1 year.Entities:
Keywords: coping; endovascular treatment; health behavior; health-related quality of life; stroke
Mesh:
Year: 2020 PMID: 32824892 PMCID: PMC7503747 DOI: 10.3390/ijerph17176014
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Sociodemographic and clinical-pathological characteristics of the patients.
| Sociodemografic and Clinical-Pathological Characteristics | Total | EVT | BMT | |
|---|---|---|---|---|
| Age (years) | 67.60 (10.40) | 66.76 (10.15) | 68.47 (10.72) | 0.406 |
| Sex (male) | 43 (52.4) | 23 (54.8) | 20 (50) | 0.204 |
| Medical history | ||||
| Psychiatric history | 11 (13.4) | 8 (19) | 3 (7.5) | 0.128 |
| Hypertension | 55 (67.1) | 27 (64.3) | 28 (70) | 0.582 |
| Diabetes mellitus | 22 (26.8) | 12 (28.6) | 10 (25) | 0.715 |
| Dyslipidaemia | 52 (63.4) | 26 (61.9) | 26 (65) | 0.775 |
| Ischemic heart disease | 42 (51.2) | 20 (47.6) | 22 (55) | 0.504 |
| Cancer | 11 (13.4) | 5 (11.9) | 6 (15) | 0.681 |
| Previous stroke | 7 (8.5) | 1 (2.4) | 6 (15) | 0.041 |
| Previous TIA | 3 (3.7) | 1 (2.4) | 2 (5) | 0.337 |
| Toxic habits | ||||
| Alcohol | 0.786 | |||
| Never | 65 (79.3) | 33 (78.6) | 32 (80) | |
| Moderate | 13 (15.9) | 7 (16.7) | 6 (15) | |
| Severe | 3 (3.7) | 1 (2.4) | 2 (5) | |
| Former | 1 (1.2) | 1 (2.4) | 0 | |
| Smoking | 0.661 | |||
| Never | 53 (64.6) | 26 (61.9) | 27 (67.5) | |
| Moderate | 11 (13.4) | 6 (14.3) | 5 (12.5) | |
| Excessive | 5 (6.1) | 3 (7.1) | 2 (5) | |
| Former | 13 (15.9) | 7 (16.7) | 6 (15) |
Values in brackets for age are standard deviations and are percentages for all the other values of the sample. BMT: Best Medical Treatment, EVT: Endovascular Treatment.
Brief Coping Questionnaire (COPE-28) Scale at 3 months and 1 year after randomization, depending on the group treatment.
| COPE-28 Items | Total | COPE-28 | COPE-28 | ||
|---|---|---|---|---|---|
| Active coping | EVT: 23 | 3.92 [1.99] | 0.267 | 3.63 [2.10] | 0.030 |
| Items 2 and 10 | BMT: 27 | 4.52 [1.83] | 4.74 [1.43] | ||
| Planning | EVT: 23 | 2.96 [1.88] | 0.465 | 2.79 [2.10] | 0.637 |
| Items 6 and 26 | BMT: 27 | 3.37 [2.10] | 3.07 [2.13] | ||
| Use of emotional support | EVT: 23 | 3.92 [2.30] | 0.753 | 4.25 [2.07] | 0.597 |
| Items 9 and 17 | BMT: 27 | 4.11 [2.08] | 4.56 [2.03] | ||
| Social support | EVT: 23 | 3.04 [1.76] | 0.195 | 3.21 [1.64] | 0.458 |
| Items 1 and 28 | BMT: 27 | 3.67 [1.64] | 3.59 [1.99] | ||
| Religion | EVT: 23 | 1.79 [2.32] | 0.574 | 2.50 [2.54] | 0.403 |
| Items 16 and 20 | BMT: 27 | 1.44 [2.06] | 1.93 [2.32] | ||
| Positive reframing | EVT: 23 | 2.54 [2.18] | 0.886 | 2.83 [1.99] | 0.164 |
| Items 14 and 18 | BMT: 27 | 2.63 [2.15] | 3.63 (2.02) | ||
| Acceptance | EVT: 23 | 4.21 [1.79] | 0.795 | 4.25 [1.65] | 0.034 |
| Items 3 and 21 | BMT: 27 | 4.33 [1.62] | 5.00 [1.39] | ||
| Denial | EVT: 23 | 1.17 [1.63] | 0.441 | 0.92 [1.25] | 0.339 |
| Items 5 and 13 | BMT: 27 | 1.56 [1.91] | 1.33 [1.75] | ||
| Humor | EVT: 23 | 1.33 [1.93] | 0.944 | 1.29 [1.85] | 0.830 |
| Items 7 and 19 | BMT: 27 | 1.37 [1.82] | 1.19 [1.67] | ||
| Self-distraction | EVT: 23 | 3.00 [2.04] | 0.499 | 2.75 [1.87] | 0.299 |
| Items 4 and 22 | BMT: 27 | 2.59 [2.21] | 3.33 [2.08] | ||
| Self-blame | EVT: 23 | 1.29 [1.57] | 0.945 | 1.33 [1.50] | 0.548 |
| Items 8 and 27 | BMT: 27 | 1.26 [1.77] | 1.63 [1.95] | ||
| Behavioral disengagement | EVT: 23 | 1.33 [1.69] | 0.728 | 0.71 [1.08] | 0.463 |
| Items 11 and 25 | BMT: 27 | 1.19 [1.33] | 0.96 [1.34] | ||
| Venting | EVT: 23 | 1.25 [1.26] | 0.496 | 1.54 [1.50] | 0.906 |
| Items 12 and 23 | BMT: 27 | 1.52 [1.50] | 1.59 [1.55] | ||
| Substance abuse | EVT: 23 | 0.21 [0.66] | 0.202 | 0.13 [0.61] | 0.697 |
| Items 15 and 24 | BMT: 27 | 0.04 [0.19] | 0.19 [0.48] |
Variables are represented as median [IQR].
Neurological and functional outcome of patients: post-treatment, at 3 months, and 1 year after a stroke.
| Neurological and Functional Scales | Total | EVT | BMT | |
|---|---|---|---|---|
| Baseline NIHSS | 16 [13−19] | 15 [11−19] | 17 [14−19] | 0.225 |
| NIHSS 24 h | 10 [4−15] | 6 [3−13] | 11 [7−17] | 0.013 |
| NIHSS 3 months | 7 [1−11] | 2 [1−12] | 5 [3−11] | 0.071 |
| NIHSS 1 year | 5 [1−7] | 4 [0−8] | 6 [1−7] | 0.484 |
| Previous BI | 100 | 100 | 100 | 1.000 |
| BI 3 months | 80 [10−98] | 80 [13−100] | 70 [10−95] | 0.184 |
| BI 1 year | 76 [60−100] | 78 [65−100] | 74 [60−95] | 0.336 |
| Previous mRS | 0 [0−0] | 0 [0−0] | 0 [0−1] | 0.355 |
| mRS 3 months | 3 [2−5] | 2 [2−5] | 3 [2−5] | 0.178 |
| mRS 1 year | 3 [2−3] | 2 [2−3] | 3 [2−3] | 0.536 |
| SIS-16 3 months | 53 [21−73] | 59 [22−75] | 48 [16−70] | 0.269 |
| SIS-16 1 year | 57 [46−76] | 60 [53−78] | 54 [37−71] | 0.178 |
Variables are represented with median [IQR]. BI: Barthel Index, mRS: Modified Rankin Scale, NIHSS: National Institute of Health Stroke Scale, SIS-16: Stroke Impact Scale-16.
The number of patients included in the favorable functional and neurological category of the evaluated scales at 3 months and 1 year after a stroke.
| Neurological and Functional Scales | 3 Months | 1 Year | ||||
|---|---|---|---|---|---|---|
| EVT | BMT | EVT | BMT | |||
| NIHSS [0–2] | 22 (81.5) | 8 (61.5) | 0.314 | 17 (60.7) | 14 (53.8) | 0.876 |
| mRS [0–2] | 21 (50) | 11 (27.5) | 0.029 | 20 (47.6) | 11 (27.5) | 0.119 |
| BI [95–100] | 16 (43.6) | 12 (35.3) | 0.881 | 17 (65.4) | 13 (52) | 0.332 |
| SIS-16 [40–80] | 27 (65.9) | 24 (60) | 0.585 | 28 (80) | 23 (74.2) | 0.574 |
Variables are represented with number of cases (percentage).
The health-related quality of life (HRQoL) perceived by participants at 3 months and 1 year after a stroke.
| HRQoL | EVT 3 Months ( | BMT 3 Months ( | EVT 1 Year ( | BMT 1 Year ( | ||
|---|---|---|---|---|---|---|
| Mobility | 0.204 | 0.635 | ||||
| I have no trouble walking | 21 (52.5) | 12 (33.3) | 18 (51.4) | 13 (41.9) | ||
| I have some trouble walking | 11 (27.5) | 16 (44.4) | 12 (34.3) | 14 (45.2) | ||
| I have to stay in bed | 8 (20) | 8 (22.2) | 5 (14.3) | 4 (12.9) | ||
| Personal care | 0.129 | 0.514 | ||||
| I have no problems with personal care | 21 (52.5) | 12 (33.3) | 20 (57.1) | 14 (45.2) | ||
| I have some difficulty in washing or dressing myself | 7 (17.5) | 13 (36.1) | 7 (20) | 10 (32.3) | ||
| I am unable to wash or dress myself | 12 (30) | 11 (30.6) | 8 (22.9) | 7 (22.6) | ||
| Daily activities | 0.645 | 0.792 | ||||
| I have no problems | 12 (30) | 8 (22.2) | 10 (28.6) | 8 (25.8) | ||
| I have some problems | 15 (37.5) | 13 (36.1) | 13 (37.1) | 13 (41.9) | ||
| I am unable to do daily activities | 13 (32.5) | 15 (41.7) | 12 (34.3) | 10 (32.3) | ||
| Pain/discomfort | 0.012 | 0.426 | ||||
| I have no pain or discomfort | 22 (55) | 10 (27.8) | 17 (48.6) | 11 (35.5) | ||
| I have moderate pain or discomfort | 11 (27.5) | 22 (61.1) | 14 (40) | 13 (41.9) | ||
| I have a lot of pain or discomfort | 7 (17.5) | 4 (11.1) | 4 (11.4) | 7 (22.6) | ||
| Anxiety/depression | 0.838 | 0.797 | ||||
| I am not anxious or depressed | 13 (32.5) | 10 (27.8) | 12 (34.3) | 12 (38.7) | ||
| I am moderately anxious or depressed | 20 (50) | 18 (50) | 18 (51.4) | 15 (48.4) | ||
| I am very anxious or depressed | 7 (17.5) | 8 (22.2) | 5 (14.3) | 4 (12.9) | ||
| EQ-5D index | 0.760 (0.177) | 0.692 (0.150) | 0.078 | 0.763 (0.160) | 0.731 (0.167) | 0.440 |
| EQ-VAS (0–100) | 60 [40–75] | 50 [21–70] | 0.053 | 58 [50–75] | 56 [40–80] | 0.707 |
The EuroQoL visual analog scale (EQ-VAS) is represented as median [IQR], while the rest of the variables are shown with the number of cases (percentage).
Variables associated with the HRQoL (EQ-VAS) at 3 months after a stroke.
| Variable | B | Standard Error | β | (CI 95%) | ||
|---|---|---|---|---|---|---|
| Lower Limit | Upper Limit | |||||
| Constant | 1.013 | 0.065 | 0.000 | 0.883 | 1.143 | |
| Age | 0.001 | 0.001 | 0.049 | 0.400 | −0.001 | 0.003 |
| Sex | −0.015 | 0.018 | 0.046 | 0.405 | −0.052 | 0.021 |
| Treatment (EVT) | 0.039 | 0.019 | 0.118 | 0.038 | 0.002 | 0.077 |
| NIHSS | 0.003 | 0.002 | 0.129 | 0.110 | −0.001 | 0.007 |
| mRS | −0.078 | 0.009 | −0.739 | 0.000 | −0.096 | −0.061 |
| Pain/discomfort dimension (EQ-5D) | −0.078 | 0.016 | −0.330 | 0.000 | −0.111 | −0.046 |
Adjusted R2 = 0.563.
Variables associated with the HRQoL (EQ-VAS) at 1 year after a stroke.
| Variable | B | Standard Error | β | (CI 95%) | ||
|---|---|---|---|---|---|---|
| Lower Limit | Upper Limit | |||||
| Constant | 1.063 | 0.066 | 0.000 | 0.930 | 1.195 | |
| Age | 0.001 | 0.001 | 0.059 | 0.319 | −0.001 | 0.003 |
| Sex | −0.016 | 0.019 | −0.050 | 0.393 | −0.054 | 0.021 |
| Treatment (EVT) | −0.131 | 3.566 | −0.003 | 0.971 | −7.266 | 7.004 |
| NIHSS | −0.001 | 0.003 | −0.023 | 0.805 | −0.006 | 0.004 |
| mRS | −0.070 | 0.011 | −0.595 | 0.000 | −0.092 | −0.048 |
| Pain/discomfort dimension (EQ-5D) | −0.099 | 0.014 | −0.441 | 0.000 | −0.127 | −0.070 |
Adjusted R2 = 0.536.